Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 11:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 207 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Fish oil capsules Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Comparison of EPA and DHA-Rich Fish Oils on Lipoprotein Metabolism In Adults

NCT02514070
View directory record Official record
Conditions
Lipoprotein Metabolism, PCSK9, Proteomics
Interventions
EPA-rich fish oil, DHA-rich fish oil
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Oct 8, 2026, 11:46 PM EDT
Completed Phase 1 Interventional

Metformin and Omega-3 Fatty Acids in Woman With a History of Early Stage Breast Cancer

NCT02278965
View directory record Official record
Conditions
Stage 0 Breast Carcinoma, Breast Neoplasms, Stage I Breast Carcinoma, Stage II Breast Carcinoma, Stage III Breast Carcinoma
Interventions
Metformin, Omega-3 fatty acids
Drug
Lead sponsor
Katherine D. Crew
Other
Eligibility
21 Years to 75 Years · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2022 · Synced Oct 8, 2026, 11:46 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Omega-3 Fatty Acid Supplementation in Older Adults

NCT01666392
View directory record Official record
Conditions
Inflammation
Interventions
Omega-3 fatty acid, Placebo
Dietary Supplement
Lead sponsor
University of Memphis
Other
Eligibility
60 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 10, 2012 · Synced Oct 8, 2026, 11:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effects of Fish Oil Supplementation on the Brain Health of Collegiate Football Athletes

NCT04796207
View directory record Official record
Conditions
Traumatic Brain Injury (TBI), Chronic Traumatic Encephalopathy (CTE)
Interventions
Fish Oil (DPA+EPA 2:1 ratio) Capsules, High Oleic Safflower Oil Capsules
Dietary Supplement
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 25 Years · Male only
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 8, 2026, 11:46 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

The Effects of DHA on Periodontitis

NCT01976806
View directory record Official record
Conditions
Periodontitis, Gingivitis, Inflammation
Interventions
Aspirin, Docosahexaenoic acid, Placebo (for Docosahexaenoic acid)
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
40 Years and older
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Oct 8, 2026, 11:46 PM EDT
Completed Early Phase 1 Interventional

Docosahexaenoic Acid (DHA) To Prevent Development of Cognitive Dysfunction Due to Chemotherapy

NCT02517502
View directory record Official record
Conditions
Cognitive Dysfunction
Interventions
DHA, Placebo
Drug
Lead sponsor
Carol Fabian, MD
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Decatur, Illinois • Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Oct 8, 2026, 11:46 PM EDT
Completed Not applicable Interventional

A Pilot Study of Fish Oil Supplementation in Hemodialysis Patients

NCT00308295
View directory record Official record
Conditions
End-Stage Renal Disease Patients on Hemodialysis
Interventions
Fish oil capsules, matched placebo capsules
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 82 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 16, 2007 · Synced Oct 8, 2026, 11:46 PM EDT
Active, not recruiting Not applicable Interventional

Low-Fat Diet and Fish Oil in Men on Active Surveillance for Prostate Cancer

NCT02176902
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
Interventions
behavioral dietary intervention, omega-3 fatty acid, laboratory biomarker analysis
Behavioral · Dietary Supplement · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
50 Years to 80 Years · Male only
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 8, 2026, 11:46 PM EDT
Completed Phase 2 Interventional Results available

Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation

NCT00167310
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Major Depression, Bipolar Disorder, Coronary Artery Disease
Interventions
Eicosapentaenoic acid (omega-3 fatty acid), Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Oct 8, 2026, 11:46 PM EDT
Completed Not applicable Interventional Results available

Vitamin D and Omega-3 Trial to Prevent and Treat Diabetic Kidney Disease

NCT01684722
View directory record Official record
Conditions
Diabetes
Interventions
Vitamin D, Omega-3 fatty acids (fish oil), Vitamin D placebo, Fish oil placebo
Dietary Supplement · Drug
Lead sponsor
University of Washington
Other
Eligibility
50 Years and older
Enrollment
1,312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Oct 8, 2026, 11:46 PM EDT
Recruiting Not applicable Interventional

Optimizing CNS DHA Delivery in Elderly Adults at Risk for Dementia

NCT06933095
View directory record Official record
Conditions
Eldery People, Cognitive Decline, Memory Decline, DHA CNS Delivery
Interventions
LPC-EPA+DHA capsules containing omega-3 fatty acids EPA and DHA esterified to lysophosphatidylcholine (LPC-EPA+DHA)(Trade name: Lysoveta)
Dietary Supplement
Lead sponsor
University of Cincinnati
Other
Eligibility
55 Years to 82 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 8, 2026, 11:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Fish Oils on Inflammation and Insulin Resistance

NCT00579436
View directory record Official record
Conditions
Metabolic Syndrome, Insulin Resistance
Interventions
omega-3 fatty acid, placebo
Drug
Lead sponsor
Philip Kern
Other
Eligibility
35 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2015
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 16, 2018 · Synced Oct 8, 2026, 11:46 PM EDT
Completed Phase 4 Interventional Results available

Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)

NCT03757585
View directory record Official record
Conditions
Non-verbal Learning Disorder, Autism Spectrum Disorder, Autism
Interventions
Open-label Treatment with Omega-3 Fatty Acids + Inositol, Open-label Treatment with N-acetylcysteine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
5 Years to 17 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Oct 8, 2026, 11:46 PM EDT
Completed Phase 3 Interventional Results available

Effect of Omega-3 Fatty Acid on Cortical Function in ADHD

NCT01883817
View directory record Official record
Conditions
Attention Deficit Disorder
Interventions
DHA Omega-3, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
5 Years to 15 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Oct 8, 2026, 11:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Large Randomized Trial of Vitamin D, Omega-3 Fatty Acids and Cognitive Decline

NCT01669915
View directory record Official record
Conditions
Cognitive Decline
Interventions
vitamin D3, omega-3 fatty acids (fish oil), Vitamin D3 placebo, Fish oil placebo
Dietary Supplement · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
60 Years to 92 Years
Enrollment
3,424 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 21, 2023 · Synced Oct 8, 2026, 11:46 PM EDT
Recruiting Not applicable Interventional

A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)

NCT06055894
View directory record Official record
Conditions
Multiple Myeloma, Smoldering, Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
Interventions
Omega-3, Curcumin, Probiotic, Whole food, plant-based diet (WFPBD)
Dietary Supplement · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 8, 2026, 11:46 PM EDT
Completed Not applicable Interventional

Novel Dietary Interventions for Treating Insulin Resistance

NCT02006394
View directory record Official record
Conditions
Insulin Resistance, Obesity, Metabolic Syndrome
Interventions
Fish Oil, Polyphenol Capsules, Corn Oil Capsules, Corn starch capsules, Reduced glycemic index bread products, Market variety bread products
Dietary Supplement · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
21 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2013 · Synced Oct 8, 2026, 11:46 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Assessment of DHA On Reducing Early Preterm Birth

NCT02626299
View directory record Official record
Conditions
Preterm Birth
Interventions
Docosahexaenoic acid - 800mg/day, Docosahexaenoic acid - 200mg/day, Placebo
Drug · Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
1,100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
3
States / cities
Kansas City, Kansas • Cincinnati, Ohio • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 30, 2021 · Synced Oct 8, 2026, 11:46 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Fish Oils and Adipose Inflammation Reduction

NCT02010359
View directory record Official record
Conditions
Obesity
Interventions
Lovaza, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
25 Years to 50 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 8, 2026, 11:46 PM EDT
Completed Not applicable Interventional

Diabetes Visual Function Supplement Study

NCT01646047
View directory record Official record
Conditions
Diabetes Mellitus - Type 1, Diabetes Mellitus - Type 2, Non-proliferative Diabetic Retinopathy
Interventions
multi-component nutritional supplement capsules, multi-component dietary supplement
Dietary Supplement
Lead sponsor
ZeaVision, LLC
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jan 22, 2015 · Synced Oct 8, 2026, 11:46 PM EDT
Not listed Phase 2 Interventional

Dose-Finding Study of SC411 in Children With Sickle Cell Disease

NCT02973360
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Docosahexaenoic Acid, Placebo
Drug
Lead sponsor
Micelle BioPharma Inc
Industry
Eligibility
5 Years to 17 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
11
States / cities
Birmingham, Alabama • Oakland, California • Gainesville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Oct 8, 2026, 11:46 PM EDT
Completed Not applicable Interventional Results available

Lycopene or Omega-3 Fatty Acid Nutritional Supplements in Treating Patients With Stage I or Stage II Prostate Cancer

NCT00402285
View directory record Official record
Conditions
Prostate Cancer
Interventions
lycopene supplement, fish oil supplement, Placebo
Dietary Supplement · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
Male only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 1, 2016 · Synced Oct 8, 2026, 11:46 PM EDT
Completed Phase 2 Interventional Results available

The Role Of Omega-3 Fatty Acids In Adolescent Depression

NCT00962598
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Omega 3 Fatty Acids, Corn oil
Drug · Dietary Supplement
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
12 Years to 19 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2018 · Synced Oct 8, 2026, 11:46 PM EDT
Completed Phase 1 Interventional Results available

A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL

NCT02268851
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma
Interventions
TGR-1202, Ibrutinib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
5
States / cities
Monterey, California • Hartford, Connecticut • Brewer, Maine + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 8, 2026, 11:46 PM EDT